Skip to content
10-Q

Quarterly Report

Oncotelic Therapeutics, Inc. OTLC

0001493152-26-023181

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 444.5M sh
Shares Diluted Q1 2026 · Mar 31, 2026 443.8M sh
Shares Diluted Q1 2026 · Mar 31, 2025 407.42M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$342.24K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$166.96K
Stockholders Equity Q1 2026 · Mar 31, 2026 $263.29M
Stockholders Equity Q1 2026 · Dec 31, 2025 $262.76M
Current Liabilities Q1 2026 · Mar 31, 2026 $18.4M
Current Liabilities Q1 2026 · Dec 31, 2025 $18.14M
Total Liabilities Q1 2026 · Mar 31, 2026 $131.74M
Total Liabilities Q1 2026 · Dec 31, 2025 $131.36M
Current Assets Q1 2026 · Mar 31, 2026 $2.07M
Current Assets Q1 2026 · Dec 31, 2025 $1.2M
Total Assets Q1 2026 · Mar 31, 2026 $393.96M
Total Assets Q1 2026 · Dec 31, 2025 $393.09M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $1.85M
Sga Expense Q1 2026 · Mar 31, 2025 $100.8K
Rd Expense Q1 2026 · Mar 31, 2026 $795
Rd Expense Q1 2026 · Mar 31, 2025 $297
Net Income Q1 2026 · Mar 31, 2026 −$2.19M
Net Income Q1 2026 · Dec 31, 2025 $249.3M
Net Income Q1 2026 · Mar 31, 2025 −$298.72K
Operating Income Q1 2026 · Mar 31, 2026 −$1.85M
Operating Income Q1 2026 · Mar 31, 2025 −$101.1K
Stock Issued Q1 2026 · Jan 31, 2026 1.6M sh
Stock Issued Q1 2026 · Jan 23, 2026 1.6M sh
Stock Issued Q1 2026 · Jul 31, 2025 2.25M sh